Welcome to University of Mumbai, Department of Biophysics

Bioinformatics Database on
"Radiosensitisers and Radioprotectors"

Home  >   Help
Names Synonyms or trade names, chemical name for the given radioprotector/sensitizer
IUPAC Name IUPAC or standard chemical name for the radioprotector/sensitizer.
Molecular Weight Molecular weight in g/mol, calculated from molecular formula
Structure 2D structure of the given radioprotector/sensitizer
Functional Groups Functional groups present in the radioprotector/sensitizer, obtained from structure
Chemical Nature Chemical, physical properties of radioprotector/sensitizer
Active Ingradients active ingradients present in the radiorotector/sensitizer(plant extract)
Actions and Indications Uses of radioprotector/sensitizer other than as a radio-modifying agent, pharmacological action, pre-clinical studies performed with its use not as radio-modifying agent.
Limitations Drawbacks or limitation of radioprotector/sensitizer, in general
Drug resistance Cells resistant or sensitive to radioprotector/sensitizer in question
Notes extra information about radiorotector/sensitizer not necessarily pertaining to radiomodifaction
Effective Dose(Experimental) The dose of the radioprotector/sensitizer that is being practised by Health care professionals at radiotherapy centers in case of clinically established drug. In case of unestablished radioprotector/sensitizer, dose that gave optimum result in majority of animal experiments. The dose mentioned will most of the time be the effective experimental dose
Mode and form of administration The mode of administration found suitable and effective in case of given radioprotector/sensitizer, also other routes it can be given through.
Form of radioprotector/sensitizer while injecting/consuming
Time of administration States the radioprotector/sensitizer administration timings and duration of drug exposure either before or after the radiation dose schedule.
Side Effects Ill effects of radioprotector/sensitizer during the treatment, which do not persisit when patients are off the radioprotector/sensitizer.
Combined action with other drugs /therapies: Drugs that are known to interact, interfere,cause adverse reactions or even able to alleviate some of the side effects when taken with given radioprotector/sensitizer and radiation treatment. other radiomodifiers acting synergistically with the radioprotector/sensitizer in question, also its interaction with metal ions/chelation.
Precaution and contraindications Information of patients regarding their gender, age and also information on how the radioprotector/sensitizer should and shouldn't be used
Dose Modification Factor(DMF) It is standard measure of effectiveness of radiomodifier.
Radiation Dose Schedule Schedule of radiation dose includes duration and dose interval timings and change in protection factors as schedule changes.
Also mentions factors that can change the effectiveness of radioprotector/sensitizer, and whether tumor protection is exhibited by a particular radioprotector.
Fractionation study Radiation fractions are decided so as to maximum SERs and also to cause less harm to normal tissues.
Various studies are done to decide the suitable fraction schedule.
Drug action Enlists oragan system, cell lines, sensitivity of which is exclusively modified by radioprotector/sensitizer.
also mentions radioprotector/sensitizer effect on cell cycle phases
Drug Target/Site of Action Molecule/s which get/s modified because of interaction with radioprotector/sensitizer.
Mechanism Description of how the radioprotector/sensitizer works or brings about expected change molecularly as well as physiologically
Maximum Tolerable Dose(MTD) The dose above which radioprotector/sensitizer causes adverse effects in patients.
Dose Limiting Toxicity(DLT) The toxicity that limits the radioprotector/sensitizer intervention to particular concentration
Biological half-life of drug Half life of radioprotector/sensitizer in body/elimination half-life measured in hours or days.
Drug levels in cells/tissues /organs radioprotector/sensitizer concentrations(quantitative) achieved in different cell, tissue or organ
Serum/Plasma drug level Highest concentration of radioprotector/sensitizer or concentration of drug achieved in serum/plasm according to dose administered and time lapsed after administration.
Drug-Tumor Diffusion: Concentration of radioprotector/sensitizer that actually reaches to tumor tissues and also the time drug takes to reach and spread to the core of the tumor.
Serum/Plasma constituents/ protein binding Binding of radioprotector/sensitizer to serum/plasma proteins and other plasma constituents
Uptake of drug/Absorption/Distribution Description of how much of the radioprotector/sensitizer or how readily the radioprotector/sensitizer is taken up by the body/organs. Comment on its bioavailability
Biotransformation Location location(organ/tissue) where the radioprotector/sensitizer is neutralized/metabolised to active metabolite.
Drug metabolite(s) The form of radioprotector/sensitizer which is actually responsible for drug's pharmacological activity and also other inanctive forms.
Associated Metabolic Enzyme(s) Enzymes involved in metabolism of radioprotector/sensitizer.
Effect on Enzymes(non-target), protein levels/influence on receptors Inhibition/induction/modification of enzymes, receptors and other proteins by radioprotector/sensitizer.
Transporters/Carriers Transporters which brings about influx and efflux of radioprotector/sensitizer.
Pharmacodynamics Changes radioprotector/sensitizer bring about in oraganism at molecular and physiological level.
Pathway(s) Pathways in which the given radioprotector/sensitizer is involved or via which the radioprotector/sensitizer is metabolised.
Route of Elimination Route by which the radioprotector/sensitizer is eliminated in human, experimental animals.
Excretion /Clearance Excretory metabolites and other information of clearance of radioprotector/sensitizer
Toxicity Values Lethal dose (LD50) values from test animals, IC50 in case of cell lines
Adverse Effects Description of toxic effects seen in humans, test animal such as organ toxicity, changes in levels of secretory products, enzymes, changes in significant blood parameters.
Toxicity when radioprotector/sensitizer is given in high doses.
Mutagenicity or
Carcinogenicity Data
Experimental Data on mutagenicity/antimutagenicity or carcinogenic/anticarcinogenicity properties of radioprotector/sensitizer
Fertility radioprotector/sensitizer effect on fertility, reproductivity of males and females.
Pregnancy radioprotector/sensitizer effect on pregnancy, if taken during gestational period.
Breastfeeding radioprotector/sensitizer secretion in breast milk.